FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants
Drug Topics
JUNE 10, 2025
Additionally, the safety profile of clesrovimab-cfor was seen to be comparable to placebo, with most adverse reactions being mild to moderate. The most common adverse reactions were injection-site erythema, injection-site swelling and rash.
Let's personalize your content